Enspryng

Active Ingredient(s): Satralizumab
FDA Approved: * August 14, 2020
Pharm Company: * GENENTECH
Category: Immunosuppressive

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Enspryng Overview

Satralizumab, sold under the brand name Enspryng, is a humanized monoclonal antibody medication that is used for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease.[3][4] The drug is being developed by Chugai Pharmaceutical, a subsidiary of Roche.[5] The most common side effects include the common cold (nasopharyngitis), headache, upper respiratory tract infection, inflammation of the lining of the stomach...

Read more Enspryng Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Satralizumab

Recent Enspryng Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Enspryng: (1 result)

Sorted by National Drug Code

• 50242-007 Enspryng 120 mg/ml Subcutaneous Injection, Solution by Genentech Inc.

Other drugs which contain Satralizumab or a similar ingredient: (1 result)

• SATRALIZUMAB